East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Acyclovir Oral Suspension USP, 200 mg/5 mL. Aurobindo Pharma’s Acyclovir Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), ZOVIRAX ® (acyclovir), of Mylan Pharmaceuticals Inc.

Acyclovir Oral Suspension are indicated for:

• Acute treatment of herpes zoster (shingles)
• Treatment of initial episodes and the management of recurrent episodes of genital herpes
• Treatment of chickenpox (varicella).